ESR1 and breast cancer: In patients with ER+ early-stage breast cancer who were candidates for gene expression profiling because the indication to administer chemotherapy was considered disputable, DMFS was longer in the genomic low- than in the high-risk group while almost all patients in the low genomic risk group had not received chemotherapy in line with the 70-GS test result.